🔬 Their partnership aims to provide a seamless solution for viral vector development and production.
💡 Wacker contributes its PLASMITEC platform, while Expression offers its LentET technology.
🚀 Together, they aim to simplify the path from research to patient delivery, accelerating timelines for biopharma clients.
Introduction:
The collaboration between Wacker Biotech US, a contract development and manufacturing organization (CDMO), and Expression Manufacturing aims to enhance the development and manufacturing processes for lentiviral-based gene and cell therapies. This partnership seeks to deliver an integrated solution for biopharmaceutical and biotechnology clients by optimizing viral vector development and production pathways.
- Wacker Biotech and Expression Manufacturing have entered into a partnership to improve lentiviral-based therapeutic solutions.
- Wacker utilizes its PLASMITEC® platform, which leverages a proprietary E. coli strain for producing high-quality plasmid DNA (pDNA).
- Expression Manufacturing contributes its LentET™ platform, recognized for its lentiviral plasmid backbone technology and advanced manufacturing capabilities.
- The collaboration is expected to streamline production processes, reducing time and complexity in transitioning from research to clinical applications.
- Key benefits of the partnership include enhanced safety through reduced recombination risks and improved potency of viral vectors.
Conclusion:
This partnership between Wacker Biotech and Expression Manufacturing represents a significant advancement in the field of gene and cell therapy. By combining their respective technologies and capabilities, they aim to provide an end-to-end solution that not only accelerates the development and manufacturing timeline but also enhances the overall safety and efficacy of lentiviral vectors. This collaboration may pave the way for more efficient therapeutic applications and improved patient outcomes in the future.
